Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia

Diabetes

Volumn 65, Issue 1, 2016, Pages 34-43

  Krieger, Jean Philippe ^a   Arnold, Myrtha ^a   Pettersen, Klaus G ^a   Lossel, Pius ^a   Langhans, Wolfgang ^a   Lee, Shin J ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; LENTIVIRUS VECTOR; GLUCOSE BLOOD LEVEL; INSULIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EATING; ENERGY BALANCE; FOOD INTAKE; GANGLION; GENE SILENCING; GLUCOSE BLOOD LEVEL; INSULIN RELEASE; MALE; MEAL; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STOMACH EMPTYING; VAGUS NERVE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ENERGY METABOLISM; GENETICS; INNERVATION; INTESTINE; METABOLISM; NODOSE GANGLION; POSTPRANDIAL STATE; SECRETION (PROCESS); SENSORY NERVE CELL; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; EATING; ENERGY METABOLISM; GASTRIC EMPTYING; GENE KNOCKDOWN TECHNIQUES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INSULIN; INTESTINES; MALE; NEURONS, AFFERENT; NODOSE GANGLION; POSTPRANDIAL PERIOD; RATS; RATS, SPRAGUE-DAWLEY; VAGUS NERVE;

EID: 84962144025     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0973     Document Type: Article

References (45)

1. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
2. FDA approves weight-management drug Saxenda [article online], 2014. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm427913.htm. Accessed 10 June 2015
3. Nakagawa A, Satake H, Nakabayashi H, et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004;110:36-43
4. Ronveaux CC, de Lartigue G, Raybould HE. Ability of GLP-1 to decrease food intake is dependent on nutritional status. Physiol Behav 2014;135:222-229
5. Berthoud HR, Neuhuber WL. Functional and chemical anatomy of the afferent vagal system. Auton Neurosci 2000;85:1-17
6. Ronveaux CC, Tomé D, Raybould HE. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. J Nutr 2015;145:672-680
7. Krieger JP, Langhans W, Lee SJ. Vagal mediation of GLP-1's effects on food intake and glycemia. Physiol Behav. 3 June 2015 [Epub ahead of print]. DOI: 10.1016/j.physbeh.2015.06.001
8. Rüttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009; 150:1174-1181
9. Labouesse MA, Stadlbauer U, Weber E, Arnold M, Langhans W, Pacheco-López G. Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. J Neuroendocrinol 2012;24:1505-1516
10. Hayes MR, Kanoski SE, De Jonghe BC, et al. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1. Am J Physiol Regul Integr Comp Physiol 2011; 301:R1479-R1485
11. Surina-Baumgartner DM, Langhans W, Geary N. Hepatic portal insulin antibody infusion increases, but insulin does not alter, spontaneous meal size in rats. Am J Physiol 1995;269:R978-R982
12. Karimian Azari E, Leitner C, Jaggi T, Langhans W, Mansouri A. Possible role of intestinal fatty acid oxidation in the eating-inhibitory effect of the PPAR-a agonist Wy-14643 in high-fat diet fed rats. PLoS One 2013;8:e74869
13. Klarer M, Arnold M, Günther L, Winter C, Langhans W, Meyer U. Gut vagal afferents differentially modulate innate anxiety and learned fear. J Neurosci 2014; 34:7067-7076
14. Arnold M, Thurnherr A, Dai Y, Graber M, Pacheco-López G, Langhans W. Intraperitoneal (IP) glucagon-like peptide-1 (GLP-1) injections and meals in rats increase intestinal lymphatic GLP-1 similarly (Abstract). Appetite 2012;59:e3
15. Norgren R, Smith GP. A method for selective section of vagal afferent or efferent axons in the rat. Am J Physiol 1994;267:R1136-R1141
16. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011;152:3103-3112
17. Sisley S, Gutierrez-Aguilar R, Scott M, D'Alessio DA, Sandoval DA, Seeley RJ. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 2014;124:2456-2463
18. de Lartigue G, Ronveaux CC, Raybould HE. Deletion of leptin signaling in vagal afferent neurons results in hyperphagia and obesity. Mol Metab 2014;3: 595-607
19. Liu C, Bookout AL, Lee S, et al. PPAR7 in vagal neurons regulates high-fat diet induced thermogenesis. Cell Metab 2014;19:722-730
20. Scott MM, Williams KW, Rossi J, Lee CE, Elmquist JK. Leptin receptor expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice. J Clin Invest 2011;121:2413-2421
21. V1.8-Cre recombinase mice. Pain 2005;113:27-36
22. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996;381:415-421
23. Qian S, Chen H, Weingarth D, et al. Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol 2002;22:5027-5035
24. Calik MW, Radulovacki M, Carley DW. A method of nodose ganglia injection in Sprague-Dawley rat. J Vis Exp 2014;93:e52233
25. Chang RB, Strochlic DE, Williams EK, Umans BD, Liberles SD. Vagal sensory neuron subtypes that differentially control breathing. Cell 2015;161: 622-633
26. 36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005;1044:127-131
27. Schjoldager BT, Mortensen PE, Christiansen J, Orskov C, Holst JJ. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 1989;34:703-708
28. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996;271:E458-E464
29. Gil-Lozano M, Mingomataj EL, Wu WK, Ridout SA, Brubaker PL. Circadian secretion of the intestinal hormone GLP-1 by the rodent L cell. Diabetes 2014;63: 3674-3685
30. Anvari M, Paterson CA, Daniel EE, McDonald TJ. Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig Dis Sci 1998;43:1133-1140
31. Imeryüz N, Yegen BC, Bozkurt A, Coşkun T, Villanueva-Peñacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997;273:G920-G927
32. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009;150: 1680-1687
33. Lenard NR, Berthoud HR. Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver Spring) 2008;16(Suppl. 3): S11-S22
34. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 2000;279:R1449-R1454
35. Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 2004;286:R269-R272
36. Nishizawa M, Nakabayashi H, Uehara K, Nakagawa A, Uchida K, Koya D. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. Am J Physiol Endocrinol Metab 2013;305:E376-E387
37. Fujiwara K, Gotoh K, Chiba S, et al. Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats. J Neurochem 2012;121:66-76
38. Vahl TP, Tauchi M, Durler TS, et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007;148:4965-4973
39. Ahlkvist L, Ahrén B. Inhibiting the cholinergic effector system of the vagus nerve reduces the insulinotropic effects of both GLP-1 and GIP (Abstract). Dia-betologia 2014;57:223
40. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013;56:965-972
41. Zhang J, Ritter RC. Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms. Am J Physiol Regul Integr Comp Physiol 2012;302:R264-R273
42. Schwartz MW, Seeley RJ, Tschöp MH, et al. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature 2013;503:59-66
43. Scarlett JM, Schwartz MW. Gut-brain mechanisms controlling glucose homeostasis. F1000Prime Rep 2015;7:12
44. Ahrén B. Hepato-incretin function of GLP-1: novel concept and target in type 1 diabetes. Diabetes 2015;64:715-717
45. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473-4488